trial

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

NCTId NCT02892422
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 528 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2019-10-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
528 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-08
Primary completion
2019-10-10
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Lu AF35700

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

102 total
Bellflower, United StatesCosta Mesa, United StatesCulver City, United StatesEscondido, United StatesGarden Grove, United StatesNational City, United StatesOceanside, United StatesOrange, United StatesSan Bernardino, United StatesTorrance, United StatesLauderhill, United StatesMiami, United States

Linked catalysts

1
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schiz — primary completion2019-10-10

Facts & assertions

4 sourced
Enrollment
528
Phase
PHASE3
Primary Completion Date
2019-10-10
Status
COMPLETED
relationships
The graph out of here
drug
Lu AF35700
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication